Morten Buus Jørgensen

Serum YKL-40: A new potential marker of prognosis and location of métastases of patients with recurrent breast cancer

Julia S. Johansen, C. Cintin, Morten Buus Jørgensen et al. · European Journal of Cancer · 1995 · 144 citations

Breast Oncology, Medicine, Pathology +8

Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial

Thomas Idorn, Filip K. Knop, Morten Buus Jørgensen et al. · Diabetes Care · 2015 · 90 citations

Plasma YKL‐40, as a prognostic tumor marker in recurrent ovarian cancer

Hannah Dehn, Estrid Høgdall, Julia S. Johansen et al. · Acta Obstetricia Et Gynecologica Scandinavica · 2003 · 80 citations

Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease

Thomas Idorn, Filip K. Knop, Morten Buus Jørgensen et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 39 citations · Full text

Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease

Thomas Idorn, Filip K. Knop, Morten Buus Jørgensen et al. · Kidney International · 2013 · 32 citations

Obesity, Metabolic Syndrome, Renal Function +13